Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma

Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma

Abstract This phase 2 study evaluated the impact of pegfilgrastim, a single-dose, long-acting granulocyte colony-stimulating factor, on the steady-state mobilization of hematopoietic stem cells into peripheral blood in patients with multiple myeloma (MM) or malignant lymphoma (ML). Efficacy and safe...

Full description

Saved in:
Bibliographic Details
Main Authors: Hideki Goto, Masashi Sawa, Shin-ichiro Fujiwara, Masaki Ri, Tadao Ishida, Masahiro Takeuchi, Kenji Ishitsuka, Masako Toyosaki, Kazutaka Sunami, Junichi Tsukada, Takashi Sonoki, Aiko Shimogomi, Yuki Ichihashi, Yoshiumi Ouchi, Toshihiro Miyamoto, Masayuki Hino, Yoshinobu Maeda, Takanori Teshima
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Multiple myeloma
Pegfilgrastim
Lymphoma
CD34
Mobilization
Peripheral blood stem cell
Online Access:https://doi.org/10.1038/s41598-025-98453-7
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This phase 2 study evaluated the impact of pegfilgrastim, a single-dose, long-acting granulocyte colony-stimulating factor, on the steady-state mobilization of hematopoietic stem cells into peripheral blood in patients with multiple myeloma (MM) or malignant lymphoma (ML). Efficacy and safety, along with CD34-positive cell mobilization outcomes were assessed in patients with MM, who were randomly assigned to pegfilgrastim (n = 30) or daily filgrastim (n = 31), and ML (pegfilgrastim only, n = 13) cohorts. In the MM cohort, CD34-positive cell counts ≥ 2 × 106/kg were achieved in 100% of patients in the pegfilgrastim group and 96.7% in the filgrastim group (difference: 3.3%; 80% confidence interval: −0.9–7.5%), demonstrating the non-inferiority of pegfilgrastim to filgrastim. All patients in the ML cohort achieved ≥ 2 × 106/kg CD34-positive cell counts. The plerixafor administration rates in the MM cohort were 50.0% and 63.3% in the pegfilgrastim and filgrastim groups, respectively, and 91.7% in the ML cohort. There were no major differences in safety measures between the two groups. Although the sample size was small, particularly in the ML cohort, a single dose of pegfilgrastim demonstrated comparable efficacy and safety to daily doses of filgrastim, indicating its potential for clinical use while reducing patient burden. Trial Registration: jRCT2011210029, NCT05007652.
ISSN:2045-2322

Similar Items